MDMaria A. Dunaykina

Maria A. Dunaykina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria A. Dunaykina has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia

    by Maria A. Dunaykina, L. N. Shelikhova, S. L. Blagov, M. A. Klimentova, M. E. Perminova, E. Yu. Osipova, R. V. Nikolaev, M. V. Efimenko, G. G. Solopova, D. N. Balashov, et al.

    Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using a TCRαβ/CD19 depletion platform is associated with a low incidence of graft-versus-host disease, however, delayed immune reconstitution increases the risk of opportunistic viral reactivation. Aim: to analyze the kinetics of pathogen-specific immune reconstitution and its impact on clinical outcomes of allo-HSCT. Materials and methods. We performed a retrospective analysis on a cohort of 265 children from the prospective database of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All patients underwent their first allo-HSCT from a haploidentical donor with TCRαβ/CD19 depletion between September 2016 and March 2022. Pathogen-specific T-cell responses were assessed by IFN-γ ELISPOT assays (cutoff ≥10 SFC/3 × 10⁵ MNC) on days +30, +60, +90, +180, and at 1 year after allo-HSCT. Results. For cytomegalovirus (CMV), the proportion of ELISPOT-positive patients increased from 38.5 to 70% during the first year after allo-HSCT. For adenovirus, the proportion of ELISPOT-positive patients was 7% on day +30, 16% on day +90, and 38–49% from day +180 to 1 year. For Epstein–Barr virus, the proportion of ELISPOT-positive patients reached 22% at 1 year after allo-HSCT. On day +30, SFC counts for CMV showed the strongest correlation with CD3⁺CD8⁺ T cells; by 1 year, this association was no longer evident (R² = 0.005; p = 0.058). CMV ELISPOT positivity on day +30 correlated with CMV reactivation (57% vs 42%; p = 0.012), reflecting the effect of antigenic stimulation on T cell expansion. On day +60, ELISPOT positivity predicted a more favorable course of viremia, including a shorter duration of viremia (4 weeks vs 6 weeks; p = 0.023) and a lower peak viral load (9587 copies/mL vs 23 525 copies/mL; p = 0.029). The cumulative risk of transplant-related mortality was 3% (95% confidence interval 2–6); the trend toward lower transplant-related mortality in patients with ELISPOT positivity on day +30 did not reach statistical significance (1% vs 4%; p = 0.798). Conclusion. Therefore, reconstitution of pathogen-specific immunity after allo-HSCT is antigen-dependent. The presence of virus-specific T cells is associated with more effective control of viremia.

  • Open Access

    Post-transplant cyclophosphamide, abatacept, and vedolizumab for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in children with acute leukemia: results of a prospective study

    by Margarita E. Perminova, Larisa N. Shelihova, Maria A. Klimentova, Daria A. Shasheleva, Rimma D. Khismatullina, Maria A. Dunaykina, Susanna K. Arakelyan, Yulia V. Skvortsova, Dmitry N. Balashov, Alexey A. Maschan, et al.

    High-dose post-transplant cyclophosphamide (PTCy) is an established method for the prevention of graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) from haploidentical donors, however data on its efficacy in the pediatric population remain limited. In this prospective study, we evaluated an improved PTCy-based GVHD prophylaxis regimen comprising the a4b7 integrin blocker vedolizumab and a co-stimulatory signal inhibitor abatacept in addition to standard treatment with PTCy and cyclosporine A. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Allogeneic HSCT was performed in children with high-risk acute leukemia in complete remission from a haploidentical (n = 54) or unrelated (n = 4) donor. Myeloablative conditioning was based on treosulfan or total body irradiation. In 97% of cases, bone marrow was used as a graft source. The engraftment rate was 98%. The cumulative risk of acute GVHD grade II-IV and III-IV was 38% and 8.6%, respectively, of acute intestinal GVHD grade II-IV - 10%, and of chronic GVHD - 7%. Transplant-related mortality after 2 years of follow-up was 3.6%, the incidence of relapse was 16%, the overall survival rate - 91%, and the event-free survival rate - 85%. Overall, the proposed GVHD prophylaxis regimen demonstrated a favorable safety profile and good tolerability, no specific adverse events were observed.

  • Open Access

    Allogeneic hematopoietic stem cell transplantation outcomes in pediatric patients with refractory acute myeloid leukemia

    by M. A. Ilyushina, L. N. Shelikhova, D. A. Shasheleva, M. A. Dunaykina, S. L. Blagov, E. E. Kurnikova, D. S. Pershin, I. I. Kalinina, Ya. O. Muzalevsky, A. S. Kazachenok, et al.

    Hematopoietic stem cell transplantation (HSCT) is known to be most effective in cancer patients in remission. In this paper, we analyzed a cohort of children with refractory acute myeloid leukemia (AML) in order to study the effectiveness of HSCT in such patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and was conducted in accordance with the principles of the Declaration of Helsinki. All the patients and/or their legal representatives signed an informed consent form for participation in the study. Our retrospective analysis included 69 patients with refractory AML (induction failure (n = 31), refractory relapse (n = 38)) whose median age was 9.4 (1.1–22) years and who had undergone HSCT between February 2012 and January 2020, with the median follow-up of 5.47 (1.9–8.9) years. Fifty patients were transplanted from haploidentical donors, 10 – from matched related donors, 9 – from matched unrelated donors. All the patients received treosulfan-based conditioning and either melphalan or thiotepa. Fifty-five cases received TCRab+/CD19+-depleted HSCs (CliniMACS), 11 patients received native bone marrow and 2 – unrelated umbilical cord blood. For post-transplant relapse prevention, 21 patients were treated with hypomethylating agents in combination with bortezomib and 48 patients received modified donor lymphocyte infusions. Primary engraftment was achieved in 66 out of 69 patients (3 patients had died before engraftment). By Day +30, 86% of patients showed complete chimerism. The cumulative incidence of grade II–IV acute graft-versus-host disease was 42%, chronic graft-versushost disease was diagnosed in 17 pts. In the entire cohort, transplant-related mortality was 7.8% and cumulative incidence of relapse was 53%. NK cell recovery by Day +30 was significantly associated with decreased incidence of relapse: patients whose absolute NK cell counts were below the median had a cumulative incidence of relapse of 76% versus 43% in patients with NK cell counts above the median (p = 0.013). At a median follow-up of 5.5 years, the event-free survival was 37 ± 11%, and the overall survival was 42 ± 10%. Remission was achieved in 86% of the patients, while long-term overall survival reached about 40%. Our findings suggest that allogeneic HSCT provides a reasonable chance of cure in children with refractory AML and creates a solid basis for further improvement. Tumor burden in the bone marrow before conditioning and early post-transplant NK cell counts in the blood were found to be the most significant prognostic factors in HSCT.


  • Open Access

    Low-dose infusions of CD45RA depleted donor lymphocytes after TCRα/β-depleted transplantation in patients with non-malignant disorders

    by S. L. Blagov, L. N. Shelikhova, D. N. Balashov, E. Y. Osipova, M. V. Efimenko, N. A. Khripkova, J. O. Muzalevskiy, M. A. Dunaikina, B. S. Pershin, A. A. Maschan, et al.

    Viral infections are frequent causes of failure among the recipients of the HSCT with graft TCRα/βand CD19depletion. Adoptive transfer of memory T-cells by CD45RA-depleted donor lymphocytes infusions (memory DLI) may be useful in control of viral infections. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The work reflects the retrospective data analysis of 51 patients with non-malignant disorders who had received low dose memory DLI after HSCT. Up to 3 doses of donor lymphocytes were administered. Median follow-up for alive patients was 30 (18–49) months. We did not observe any allergic reactions, septic complications after memory DLI. The cumulative incidence of a de novo acute GVHD after DLI was 10% (95% CI: 4–22). Among 41% patients (n = 21) was detected CMV in the blood. In 73% of them (n = 16) CMV was detected before first DLI. Among patients who received DLI, 53% (n = 27) had documented appearance of virus-specific lymphocytes in peripheral blood (ELISPOT assay).Thus, the infusion of memory T-cells at a dose of 25–100 αβ103/kg body weight of the recipient for CD3+ in the case of HSCT from a haploidentical donor and 100–300 αβ103/kg for an unrelated HSCT. Infusions of low dose memory T-lymphocytes after transplant engraftment are safe, potentially effective and constitute a simple measure to prevent infections in the setting of alpha/beta T-cell-depleted transplantation.